Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Gastroesophageal Reflux Disease: Pathophysiology and Treatments Available


Affiliations
1 Rajendra Institute of Technology and Sciences, Sirsa Haryana, India
2 Chitkara School of Pharmaceutical Sciences, Chitkara University, Barotiwala HP, India
3 NCRD's Sterling Institute of Pharmacy, Navi Mumbai, India
     

   Subscribe/Renew Journal


Gastroesophageal reflux disease (GERD) is primarily a motility disorder. Escape of gastric contents into the esophagus occurs as a consequence of an incompetent gastroesophageal barrier. This barrier is weakened in the presence of an abnormally functioning Lower Esophageal Sphincter (LES). This review is focused on the epidemiology, pathophysiology and treatments of gastro-oesophageal reflux disease.

Keywords

Reflux, Proton Pump Inhibitors, H2 Receptor Antagonists, Radiofrequency.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Reynolds JC. Influence of pathophysiology, severity and cost on the medical management of gastroesophageal reflux disease. Am J Health- Syst Pharm 1996; 53 (Suppl 3): S5-S12.

  • DeVault KR and Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 867-876.

  • Zhu H, Pace F, Sangaletti O, Bianchi Porro G. Features of symptomatic gastroesophageal reflux in elderly patients. Scand J Gastroenterol 1993; 28: 235-238.

  • Nandurkar S and Talley NJ. Epidemiology and natural history of reflux disease. Bailliers Best Pract Res Clin Gastroenterol 2000; 14: 743-757.

  • Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl 1): 24-29.

  • Hu WH, Hui WM, Lam C L and Lam SK. Anxiety and depression are co-factors determining health care utilization in patients with dyspepsia: a Hong Kong population based study. Gastroenterology 1997; 112 (suppl 1): A153.

  • Dent J, El-Serag HB, Wallander M-A, Johansson S. Epidemiology of gastro-oesophageal refl ux disease: a systematic review. Gut 2005; 54: 710-17.

  • Kitchin LI and Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med. 1991; 151: 448-454.

  • Fennerty MB, Castell D and Fendrick AM. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Arch Intern Med. 1996; 156: 477- 484.

  • Orlando RC. Textbook of Gastroenterology. Reflux esophagitis.2nd ed. Philadelphia: J.B. Lippincott Company; 1995:1214 - 44.

  • Kahrilas PJ. GERD pathogenesis, pathophysiology and clinical manifestations. Cleve Clin J Med 2003; 70 (suppl 5): S4-19.

  • Paul M and Nicholas T. Gastro-esophageal reflux disease. Lancet 2006; 367: 2086-2100.

  • Mittal RK and Balaban DH. Mechanisms of disease: The esophagogastric junction. N Engl J Med. 1997; 336: 924- 938.

  • Yamato S, Saha J and Goyal RK. Role of nitric oxide in lower esophageal sphincter relaxation to swallowing. Life $5. 1992; 50: 1263-1272.

  • Smith C. Gastroesophageal reflux disease. US Pharmacist 1999; 24: 77-86.

  • Ogorek CP. Haubrich WS, Schaffner F and Berks E. Gastroenterology. Gastroesophageal reflux disease. 5th ed. Philadelphia: W.B. Saunders; 1995:445- 467.

  • Zeiter DK and Hyams JS. Gastroesophageal reflux: Pathogenesis, diagnosis, and treatment. Allergy Asthma Proc. 1999; 20: 4549.

  • Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol. 1997; 92(Suppl 4):30s-35s.

  • Kahrilas PJ. GERD pathogenesis, pathophysiology and clinical manifestations. Cleve Clin J Med 2003; 70 (suppl 5): S4-19.

  • Boyce HW. Therapeutic approaches to healing esophagitis. Am J Gastroenterol. 1997; 92 (Suppl 4):22s-27s.

  • Eva MV and Maya AT. Pharmacological strategies for treating Gastro-esophageal reflux disease. Clinical Therapeutics. 2000; 22 (6): 654-672.

  • Maton PN and Burton ME. Antacids revisited: A review of their clinical pharmacology and recommended therapeutic use of Drugs. 1999; 57: 855-870.

  • Jaspersen D, Diehl KL and Schoeppner H. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oeso- phagitis. Aliment Phurmacol Ther. 1998; 12:49-52.

  • Tytgat GN, Heading RC and Muller-Lissner. Contemporary understanding and Management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 2003; 18: 291-301.

  • DeVault KR and Castell DO. The practice parameters committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-1442.

  • Self-directed treatment of intermittent heartburn: A randomized, multicenter, double-blind, placebo-controlled evaluation of antacid and low doses of an H,-receptor antagonist (famotidine). Am J Ther. 1995; 2: 304-3 13.

  • Schindlbeck NE, Klauser AG and Voderholzer WAl. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995; 155:1808-1812.

  • Xue S, Katz PO and Banerjee P. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-1356.

  • Chiba N, De Cara CJ, Wilkinson JM and Hunt RH. Speed of healing and symptom relief in grade II to IV gastrooesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798-1810.

  • Radu T and Donald OC. Gastro-esophageal reflux disease: Natural history and long term medical and surgical outcomes. Clinical cornerstone 2003; 5 (4): 51-57.

  • Barradell LB, Fauda D and McTavish D. Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; 44: 225-250.

  • Cremonini F, Wise J, Moayyedi P and Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: A meta-analysis. Am J Gastroenterol 2005; 100: 1226-32.

  • Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm. 1996; 53:140-1415.

  • Behar J and Ramsby G. Gastric emptying and antral motility in reflux esophagitis: Effect of oral metoclopramide. Gastroenterology. 1978; 74: 253-256.

  • Nebel OT, Fomes NF and Caste11 DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis. 1976; 21: 953-956.

  • Branton SA, Hinder RA and Floch NR. Surgical treatment of gastroesophageal reflux disease. In: Caste11 DO, Richter JE, eds. The Esophagus. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:51 l-525.

  • Shapira AR, Stein HJ and Scwartz D. Endoluminal methods of treating gastroesophageal reflux disease. Dis Esophagus 2002; 15:132-36.

  • Dmitry O and Brant O. New alternatives in the management of gastroesophageal reflux disease. The American journal of surgery 2003; 186: 106-111.

  • Saleem I, James DG, Arnold GC and Daniel HT. Use of radiofrequency ablation of the lower esophageal sphincter to treat recurrent gastroesophageal reflux disease. Journal of pediatric surgery 2004; 39 (3): 282-286.

  • O'Connor KW and Lehman GA. Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux: A pilot study of 10 medically intractable patients. Gasrointest Endosc 1984; 30:275.

  • Couve, A., Moss, S. J. and Pangalos, M. N. GABA (B) receptors: A new paradigm in G protein signaling. Mol Cell Neurosci 2000; 16:296−312.

  • Billinton, A., Ige, A. O., Bolam, J. P., White, J. H., Marshall, F. H. and Emson, P. C. Advances in the molecular understanding of GABA(B) receptors. Trends Neurosci 24, 2001; 277−282.

  • Bowery, NG, Bettler, B, Froestl, W, Gallagher, JP, Marshall, F and Raiteri, M. International Union of Pharmacology. XXXIII. Mammalian gamma-amino butyric acid (B) receptors: structure and function. Pharmacol Rev 2002; 54:247−264


Abstract Views: 208

PDF Views: 1




  • Gastroesophageal Reflux Disease: Pathophysiology and Treatments Available

Abstract Views: 208  |  PDF Views: 1

Authors

Pankaj Rakha
Rajendra Institute of Technology and Sciences, Sirsa Haryana, India
Raj Kumar
Rajendra Institute of Technology and Sciences, Sirsa Haryana, India
Supriya
Rajendra Institute of Technology and Sciences, Sirsa Haryana, India
Nidhi
Rajendra Institute of Technology and Sciences, Sirsa Haryana, India
Manju Nagpal
Chitkara School of Pharmaceutical Sciences, Chitkara University, Barotiwala HP, India
Gitika Arora
NCRD's Sterling Institute of Pharmacy, Navi Mumbai, India

Abstract


Gastroesophageal reflux disease (GERD) is primarily a motility disorder. Escape of gastric contents into the esophagus occurs as a consequence of an incompetent gastroesophageal barrier. This barrier is weakened in the presence of an abnormally functioning Lower Esophageal Sphincter (LES). This review is focused on the epidemiology, pathophysiology and treatments of gastro-oesophageal reflux disease.

Keywords


Reflux, Proton Pump Inhibitors, H2 Receptor Antagonists, Radiofrequency.

References